# Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation

> **NCT04711226** · PHASE2 · WITHDRAWN · sponsor: **Anelixis Therapeutics, LLC**

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** AT-1501

## Key facts

- **NCT ID:** NCT04711226
- **Lead sponsor:** Anelixis Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-19
- **Primary completion:** 2024-06
- **Final completion:** 2026-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711226, "Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04711226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*